FDA Class II Recall: Teva's Estradiol Tablets Impacted by Cardinal Health's CGMP Storage Deviations
Cardinal Health initiated a Class II recall for Teva Pharmaceuticals' Estradiol Tablets (ANDA040197) due to critical CGMP deviations involving temperature excursions. This event, impacting nationwide USA distribution, underscores significant supply chain vulnerabilities for essential hormone therapies. Procurement directors must diversify Estradiol sourcing, while regulatory affairs heads must strengthen temperature control protocols to mitigate risks and ensure compliance, safeguarding patient access and business continuity.
FDA Class II Recall for Teva's Estradiol Tablets: Critical CGMP Storage Deviations Identified
The U.S. Food and Drug Administration (FDA) has classified a voluntary recall initiated by Cardinal Healthcare for Teva Pharmaceuticals USA, Inc.'s Estradiol Tablets USP, 0.5MG, as Class II. This recall, identified as D-0180-2024, specifically targets Batch 100023687 of the 100-tablet presentation (NDC: 0555-0899-02), which holds an application number of ANDA040197. The primary reason for this regulatory action stems from critical Current Good Manufacturing Practice (CGMP) deviations, specifically the exposure of these products to temperatures outside their labeled storage conditions. For procurement directors and supply chain VPs, this event signals an immediate need to verify inventory and distribution channels for the affected batch. The Class II classification indicates that while the probability of serious adverse health consequences is remote, temporary or medically reversible adverse health consequences are possible. This directly translates to potential patient safety risks and necessitates prompt action from distributors and pharmacies to remove the affected product from circulation, preventing further exposure and safeguarding patient well-being.
Commercial Impact and Supply Chain Vulnerabilities for Estradiol
This recall event, initiated by Cardinal Healthcare, a significant distributor based in Dublin, OH, highlights the critical interplay between manufacturers and their distribution partners in maintaining product quality and supply chain integrity. Teva Pharmaceuticals USA, Inc., located in North Wales, PA, is the manufacturer of the Estradiol Tablets, a widely used hormone therapy. The recall's nationwide USA distribution pattern means that pharmaceutical wholesalers, pharmacies, and ultimately patients across the country could have been impacted by the single unit of the specified batch. For business development executives, this incident underscores the fragility of single-source distribution models and the imperative of robust quality agreements with logistics providers. Procurement teams must immediately assess their exposure to this specific NDC (0555-0899-02) and evaluate the broader implications for their Estradiol supply. While the quantity recalled was reported as one unit, the underlying CGMP deviation points to a systemic issue that could affect other batches or products if not thoroughly addressed, posing a risk of future supply disruptions and potential market shortages for this essential medication.
Recurring Regulatory Challenges in Pharmaceutical Distribution: A Pattern of Storage Excursions
This incident is not an isolated event within the pharmaceutical distribution landscape. ChemLifeIntel's intelligence indicates a recurring pattern of regulatory challenges related to storage conditions. Notably, Cardinal Health Inc. itself faced a Class II recall for XIGDUO XR due to similar storage temperature excursions, as reported on 2026-06-16. Furthermore, other firms like Amneal Pharmaceuticals have encountered Class II recalls linked to CGMP deviations, as seen with their Nizatidine Oral Solution. For regulatory affairs heads and supply chain VPs, these parallel events emphasize a systemic vulnerability across the industry in maintaining stringent environmental controls throughout the supply chain. The consistent recurrence of temperature excursion-related recalls signals that the FDA is intensifying its scrutiny on distribution practices. Companies must proactively invest in advanced temperature monitoring systems, conduct regular risk assessments of their logistics networks, and implement rigorous training for personnel involved in handling temperature-sensitive pharmaceutical products to mitigate these pervasive risks and ensure continuous compliance.
Strategic Sourcing for Estradiol: Mitigating Future Supply Disruptions
Given the Class II recall of Teva's Estradiol Tablets due to CGMP storage deviations, procurement directors must prioritize strategic sourcing to insulate their operations from future supply chain vulnerabilities. While the current knowledge graph does not specify alternative suppliers for Estradiol, the commercial imperative is clear: identify and qualify multiple manufacturers and distributors. This involves a comprehensive due diligence process that extends beyond pricing to include a thorough evaluation of a supplier's quality management systems, historical regulatory compliance, and robust temperature control capabilities throughout their supply chain. Diversifying the supplier base for critical molecules like Estradiol minimizes reliance on a single point of failure and enhances resilience against unforeseen regulatory actions or logistical failures. Business development executives should also explore partnerships with manufacturers demonstrating superior quality and supply chain integrity, potentially leveraging this market disruption to secure more reliable long-term supply agreements and gain competitive advantage in the hormone therapy segment.
Post-Recall Remediation and Ongoing Compliance Expectations
The recall, initiated on January 26, 2022, was officially terminated by the FDA on September 29, 2024, indicating that Cardinal Healthcare completed all necessary actions to address the specific recalled batch. However, the termination of a recall does not absolve firms of the underlying CGMP obligations. For regulatory affairs and quality assurance teams, this event necessitates a thorough root cause analysis to understand why products were exposed to out-of-specification temperatures and to implement comprehensive corrective and preventive actions (CAPAs). This includes reviewing and potentially upgrading storage facilities, transportation protocols, and quality control procedures. The FDA expects continuous improvement in quality management systems. Failure to address the systemic issues identified by such deviations could lead to further regulatory scrutiny, including potential 483 observations during future inspections, or even more severe actions like Warning Letters or Import Alerts, which would have significant commercial repercussions and impact market access for Teva's products.